NASDAQ

Lipocine Inc. (LPCN)

523 Thanks from members

Lipocine Inc. ($LPCN) presents a data-contested special situation following a Phase 3 trial miss for LPCN 1154 in postpartum depression, balanced by extended cash runway to August 2027 and ongoing TLANDO commercial royalties.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →